Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
Oncotarget|July 25, 2018
RET fusions observed in lung and colorectal cancers are sensitive to ponatinibJoseph M Gozgit, Tzu-Hsiu Chen, Youngchul Song, et al.
Medrxiv : the Preprint Server for Health Sciences|August 23, 2023
Oral SARS-CoV-2 host responses predict the early COVID-19 disease courseWilliam T Seaman, Olive Keener, Wenwen Mei, et al.
Research Square|August 30, 2023
Oral SARS-CoV-2 host responses predict the early COVID-19 disease courseWilliam T Seaman, Olive Keener, Wenwen Mei, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2013
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer modelsJoseph M Gozgit, Rachel M Squillace, Matthew J Wongchenko, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
A semi-quantitative, rapid, point of care SARS-CoV-2 serologic assay predicts neutralizing antibody levelsAlena J Markmann, D Ryan Bhowmik, Baowei Jiang, et al.
Molecular Cancer Therapeutics|January 13, 2012
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer modelsJoseph M Gozgit, Matthew J Wong, Lauren Moran, et al.
Pageof 13